Ava Shamban

Ava Shamban

Auto-generated profile, based on publicly available information

Ava Shamban

Dr. Shamban is with AVA MD in Beverly Hills, California

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
ASAva T. Shamban
Ava T. Shamban
Background: KYBELLA, ATX-101, is an injectable form of sodium deoxycholic acid. It is currently the only Food and Drug Administration–approved injectable drug for the reduction of submental fat. Objectives: A literature review and discussion of the treatment of submental fat. Results: KYBELLA is a well-tolerated alternative for the treatment of submental fat. Conclusions: KYBELLA is a safe and efficacious, first in class, injectable drug for the reduction of submental fat.

30 September 2021 in Dermatologic Surgery
Verified
Journal Article
Open access
HSHema Md Sundaram
Hema Md Sundaram
ASAva Shamban
Ava Shamban
JSJoel Schlessinger
Joel Schlessinger
JKjoely kaufman
joely kaufman
JJJohn Joseph
John Joseph
LELaura Eaton-Jankov
Laura Eaton-Jankov
BACKGROUND: The perioral region is highly mobile and subject to multifactorial changes during aging. Resilient Hyaluronic Acid Redensity (RHAR), an RHA filler, was developed with the aim of optimizing outcomes in dynamic facial areas. OBJECTIVE: This randomized, blinded, multicenter clinical study aimed to demonstrate superiority of RHAR over no-treatment control for correction of moderate-to-severe dynamic perioral rhytides. MATERIALS AND METHODS: Blinded live evaluator assessments of efficacy included improvement in perioral rhytides severity using a proprietary scale (Perioral Rhytids Severity Rating Scale [PR-SRS]) and the Global Aesthetic Improvement Scale. Subjects self-assessed their results with FACE-Q, a validated patient-reported outcome measure, and satisfaction scales. Safety was monitored throughout the study based on common treatment responses (CTRs) and adverse events (AEs). RESULTS: The primary efficacy end point was achieved, with the treatment group showing statistically significant superiority over the control group at Week 8 (80.7% vs 7.8% responder rate by PR-SRS, p < .0001). Most patients (66%) were still responders at Week 52 (study completion). Most AEs were CTRs after perioral injection of a dermal filler, and none was a clinically significant treatment-related AE. CONCLUSION: Resilient Hyaluronic Acid Redensity is effective and safe for the correction of dynamic perioral rhytides in all Fitzpatrick phototypes, with marked durability.

4 April 2019 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
ASAva Shamban
Ava Shamban

28 November 2022 in Dermatologic Surgery
Verified
Journal Article
Open access
JDJeffrey S. Dover
Jeffrey S. Dover
SHShannon Humphrey
Shannon Humphrey
ZLZ. Paul Lorenc
Z. Paul Lorenc
ASAva Shamban
Ava Shamban
TGTodd Gross
Todd Gross
DVDomenico Vitarella
Domenico Vitarella
BACKGROUND: Simultaneous treatment of moderate-to-severe upper facial lines is reflective of real-world clinical practice. OBJECTIVE: To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and lateral canthal (LC) lines. METHODS: In this open-label, single-arm Phase 2 study, patients (48 enrolled, 94% completed, follow-up 24–36 weeks) received DAXI 40U (glabellar), 32U (forehead), and 48U (LC) lines. Key efficacy endpoints: percentages of patients achieving none/mild wrinkle severity (investigator-rated) for each upper facial line scale at Week 4. RESULTS: At Week 4, most patients achieved none/mild wrinkle severity (investigator-rated): glabellar (96%), forehead (96%), and LC (92%). Median times to loss of none/mild response (investigator- and patient-rated) among all patients were: 24.6 (glabellar), 20.9 (forehead), and 24.9 (LC) weeks; and 25.0, 24.0, and 28.1 weeks, respectively, among Week-4 responders. At Week 4, most patients reported improvements (Global Aesthetic Improvement Scale: 96%-98%) and high satisfaction rates (85%-98%). Five patients experienced treatment-related adverse events: injection-site erythema (3 patients/7 events), facial discomfort (2 patients/2 events), and headache (1 patient/1 event). No patients experienced eyebrow or eyelid ptosis. CONCLUSION: Simultaneous treatment of upper facial lines with DAXI was well tolerated and demonstrated high response rates, extended duration, and high patient satisfaction. CLINICAL TRIAL REGISTRY: https://clinicaltrials.gov/ct2/show/NCT04259086.

1 November 2015 in Facial Plastic Surgery Clinics of North America
Verified
Journal Article
Closed access
ASAva Shamban
Ava Shamban

1 January 2025
Verified
Journal Article
Closed access
ASAva Shamban
Ava Shamban
WRWendy E. Roberts
Wendy E. Roberts
VBVivian Bucay
Vivian Bucay
SCSuneel Chilukuri
Suneel Chilukuri
ESEva Simmons-O’bRien
Eva Simmons-O’bRien
DODiane Orlinsky
Diane Orlinsky